Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

HFpEF: a misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

HFpEF: a misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon
Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and present results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials.

Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and present results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials. With question to test your knowledge.

Down-titration of diuretics predicts achievement of target dose of ARNI in real-world HFrEF patients

Literature - Jan. 21, 2020 - Pharithi RB et al., - ESC Heart Fail. 2020.

Sacubitril-valsartan was well tolerated in stable HFrEF patients in a real-world population. Target dose was achieved in most patients and was linked to down-titration of diuretic dose.

Clinical phenotype-based HFpEF subgroups respond differently to aldosterone antagonist therapy

Literature - Jan. 15, 2020 - Cohen JB et al., - JACC Heart Fail. 2020

Three phenogroups were identified in TOPCAT HFpEF patients, ranging from a low-risk group with mild symptoms to a high-risk obese, diabetic group with advanced symptoms that responded well to spironolactone.

Effects of SGLT2 inhibitor on clinical outcomes in acute decompensated HF patients

Literature - Jan. 14, 2020 - Damman K et al., - Eur J Heart Fail. 2020

This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD
The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.

The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.

ARNI use safe and effective in elderly HFrEF patients

Literature - Jan. 13, 2020 - Esteban-Fernández A et al., - Rev Esp Geriatr Gerontol. 2019.

This prospective registry study of a real-world cohort of elderly HFrEF patients showed that sacubitril/valsartan was safe and effective, even in those >80 years.

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD
Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.

Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.

No improvement in exercise ability with SGLT2i in two HF trials, one in HFrEF and one in HFpEF patients

News - Jan. 6, 2020

Results of the EMPERIAL-Reduced and EMPERIAL-Preserved trials were announced, which both showed no benefit in exercise ability with use of empagliflozin in HFrEF and HFpEF patients, respectively.

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD
A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.

A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.

SGLT2 inhibition in CKD: Discussing the key questions and evidence

EBAC-accredited E-Learning

Online-CME - This course consists of 3 lectures.
This course consists of 3 lectures.

This video series addresses the effect of SGLT2i on kidney outcomes in diabetes patients with chronic kidney disease (CKD). Member registration (free) is needed to enroll in this course.

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD
Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.

Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.

Recent hospitalizations for HF may identify HFpEF at higher risk that may benefit from ARNI

Literature - Dec. 2, 2019 - Vaduganathan M et al., - J Am Coll Cardiol. 2019

PARAGON-HF data suggest that patients with HFpEF with a recent hospitalization have higher rehospitalization rates than those with more distant or no hospitalization, and they may respond better to sacubitril/valsartan.